BioVersys Raises $90 Million in Swiss IPO for Antibacterial Treatments

Swiss biotech BioVersys AG successfully launched its initial public offering (IPO) on February 7, 2025, with shares priced at 36 Swiss francs, leading to a market valuation of 213 million Swiss francs. The company raised 90 million francs from the IPO, which will primarily fund the development of its BV100 treatment for serious infections caused by multidrug-resistant bacteria, particularly linked to ventilator-associated pneumonia and bloodstream infections. Additionally, funds will support the advancement of alpibectir, a tuberculosis treatment developed in collaboration with GSK. CEO Marc Gitzinger heralded the IPO as a significant milestone, emphasizing the company's commitment to tackling antibiotic resistance and enhancing its clinical pipeline. The shares are set to be included in the Swiss Performance Index by February 10. This IPO marks a notable moment for the biotech sector, especially in addressing pressing public health challenges related to drug-resistant infections.